Business
Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™
The next step of the collaboration will explore potential future applications of the LIBERTY system, including its potential capabilities for remote
About this update from Microbot Medical Inc.
[{"type":"text","content":"The next step of the collaboration will explore potential future applications of the LIBERTY system, including its potential capabilities for remote endovascular procedures\nBRAINTREE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today reports that the first phase of the previously announced collaboration with Corewell Health has been completed, which demonstrated the LIBERTY® System's technical capabilities and outlines potential future applications in a range of endovascular interventions. The objective of the collaboration, which will take place in multiple phases, is to enable telerobotics between remote centers by utilizing the LIBERTY System. The agreement with Corewell Health includes the right to mutually evaluate the LIBERTY System for remote procedures and it is being led by Ryan Madder, M.D., Section Chief of Interventional Cardiology and Director of the Cardiac Cath Lab at Corewell Health in Grand Rapids, Michigan. Dr. Madder and colleagues have recently published an abstract reflecting the results of the first phase of the aforementioned collaboration in the Journal of the American College of Cardiology: Cardiovascular Interventions, highlighting the Technical Success of Coronary Guidewire and Stent Delivery Using a Novel Miniaturized Robotic System in a Pre-Clinical Study. About Microbot MedicalMicrobot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, with the goals of improving clinical outcomes for patients and increasing accessibility through the natural and artificial lumens within the human body. The LIBERTY® Endovascular Robotic Surgical System aims to improve the way surgical robotics are being used in endovascular procedures today, by eliminating the need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and physician strain. The Company believes the LIBERTY® Endovascular Robotic Surgical System’s remote operation has the potential to be the first system to democratize endovascular interventional procedures. Further information about Microbot Medical is available at http://www.microbotmedical.com. Safe Harbor Statements to future financial and/or operating results, future grow...